Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling

Artemether-lumefantrine (AL) is the most widely-recommended treatment for uncomplicated Plasmodium falciparum malaria worldwide. Its safety and efficacy have been extensively demonstrated in clinical trials; however, its performance in routine health care settings, where adherence to drug treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Challenger, Joseph D., Bruxvoort, Katia, Ghani, Azra C., Okell, Lucy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680187/
https://www.ncbi.nlm.nih.gov/pubmed/29123086
http://dx.doi.org/10.1038/s41467-017-01352-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680187/
https://www.ncbi.nlm.nih.gov/pubmed/29123086
http://dx.doi.org/10.1038/s41467-017-01352-3

Ejemplares similares